G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
News
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly…
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis”…
tru Independence Adds $1B Family Office Seven Mile Advisory
Multifamily office taps tru for ability to support existing clients while enabling growth PORTLAND, Ore.–(BUSINESS…
Helios Technologies Promotes Rick Martich to President of Hydraulics, Americas
SARASOTA, Fla.–(BUSINESS WIRE)–Helios Technologies, Inc. (NYSE: HLIO) (“Helios” or the “Company”), a global leader in…
Valmont Industries, Inc. Announces Partnership With Peerless-AV
OMAHA, Neb.–(BUSINESS WIRE)–Valmont® Industries, Inc., a global leader that provides vital infrastructure and advances agricultural…
As Generative AI Drives Urgency for AI Regulations, Most Companies Unprepared for New Requirements: Verta Insights Study
MENLO PARK, Calif.–(BUSINESS WIRE)–#ai–Verta, the Operational AI company, today previewed findings from the 2023 AI…
Citizens Business Conditions Index™ Bounces Back in Q1
Respondents seeing revenue increases broadly despite possible recession risk PROVIDENCE, R.I.–(BUSINESS WIRE)–#CBCI–Citizens announced today that…
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6…
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6…
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company…
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company…
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and…
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and…
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…